Responses of patients with Bartter's syndrome to angiotensin III and angiotensin II-(3-8)-hexapeptide. 1985

T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla

Studies were conducted to determine whether or not angiotensin III [AIII] and angiotensin II-(3-8)-hexapeptide [ANG-(3-8)] have their own specific arteriolar binding sites different from angiotensin II [AII] binding site(s) in man. Four patients with Bartter's syndrome were given asn1-,val5-AII by iv infusion at rates of 10, 20, 50 and 100 pmol/kg X min, each for 7 min. One hour later AIII was infused iv in the same 4 patients at rates of 50, 100, 250 and 500 pmol/kg X min, each for 7 min. After 100 or 150 mg/day of indomethacin treatment for 7 days, the same AII and AIII infusions were repeated. All patients showed blunted pressor responses to both AII and AIII before indomethacin and the responses were improved after indomethacin. Moreover, increment curves of blood pressure for AII were almost identical with those for AIII in individual patients both before and after indomethacin. ANG-(3-8) was infused iv in 3 normal men and 3 of the 4 patients with Bartter's syndrome at a rate of 3.500 pmol (2.838 ng)/kg X min for 15 min. Blood pressure rose in the normal men (12/12 mmHg on the average) but did not rise in the patients. These results suggest that AII, AIII and ANG-(3-8) have the same arteriolar binding sites in man.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
January 1989, Polish journal of pharmacology and pharmacy,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
April 1971, The Journal of clinical endocrinology and metabolism,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
March 1976, The New England journal of medicine,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
November 1976, Circulation research,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
December 1976, Pediatric research,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
July 1981, Japanese heart journal,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
August 1992, European journal of pharmacology,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
October 1977, British medical journal,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
December 1988, Neuroscience,
T Kono, and F Ikeda, and A Taniguchi, and H Imura, and F Oseko, and M Yoshioka, and M C Khosla
December 1994, Kidney international,
Copied contents to your clipboard!